144 related articles for article (PubMed ID: 34898046)
21. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
23. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
24. Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Liu M; Fan H; Li T; Sihong L; Qiao S; Bi J
Pathol Res Pract; 2020 Jul; 216(7):152962. PubMed ID: 32534699
[TBL] [Abstract][Full Text] [Related]
25. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
26. CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.
Filippone MG; Gaglio D; Bonfanti R; Tucci FA; Ceccacci E; Pennisi R; Bonanomi M; Jodice G; Tillhon M; Montani F; Bertalot G; Freddi S; Vecchi M; Taglialatela A; Romanenghi M; Romeo F; Bianco N; Munzone E; Sanguedolce F; Vago G; Viale G; Di Fiore PP; Minucci S; Alberghina L; Colleoni M; Veronesi P; Tosoni D; Pece S
Nat Commun; 2022 May; 13(1):2642. PubMed ID: 35550508
[TBL] [Abstract][Full Text] [Related]
27. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
28. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
29. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8
Ji J; Zhou C; Wu J; Cai Q; Shi M; Zhang H; Yu Y; Zhu Z; Zhang J
Int J Med Sci; 2019; 16(8):1142-1148. PubMed ID: 31523177
[No Abstract] [Full Text] [Related]
31. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract][Full Text] [Related]
32. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
34. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.
Thanindratarn P; Dean DC; Feng W; Wei R; Nelson SD; Hornicek FJ; Duan Z
Eur Spine J; 2020 Dec; 29(12):3214-3228. PubMed ID: 32691223
[TBL] [Abstract][Full Text] [Related]
36. Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockade.
Vlachostergios PJ
Curr Urol; 2021 Dec; 15(4):234-237. PubMed ID: 35069089
[TBL] [Abstract][Full Text] [Related]
37. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
38. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract][Full Text] [Related]
39. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
40. CDK12 and PAK2 as novel therapeutic targets for human gastric cancer.
Liu H; Shin SH; Chen H; Liu T; Li Z; Hu Y; Liu F; Zhang C; Kim DJ; Liu K; Dong Z
Theranostics; 2020; 10(14):6201-6215. PubMed ID: 32483448
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]